SAN DIEGO - Janux Therapeutics, Inc. (NASDAQ:JANX) has announced promising clinical data for two of its cancer drug candidates, JANX007 and JANX008, being developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and various solid tumors, respectively.
The company's Phase 1a clinical trial data for JANX007 in mCRPC, as of February 12, 2024, revealed that 83% of subjects achieved a 50% or greater decline in prostate-specific antigen (PSA) levels with a dose of at least 0.2mg. Additionally, 56% of subjects saw a similar decline with a starting dose of at least 0.1mg. No instances of Cytokine Release Syndrome (CRS) above Grade 2 were reported in any cohort, indicating a favorable safety profile.
Similarly, early data from the JANX008 trial in solid tumors showed a subject with non-small cell lung cancer (NSCLC) achieved a partial response with a 100% reduction in the target lung lesion and elimination of liver metastasis without any observed CRS or treatment-related adverse events (TRAEs).
The partial response has been maintained for at least 18 weeks. Across all cohorts, no CRS greater than Grade 1 was reported, and no serious adverse events or dose-limiting toxicities have been observed.
These results suggest that Janux's Tumor Activated T Cell Engager (TRACTr) platform, which aims to activate the immune system specifically within the tumor environment, may offer a promising approach for treating solid tumors that have historically been challenging to address with conventional therapies.
Janux is continuing dose optimization for both JANX007 and JANX008 to further improve efficacy while maintaining safety. The company plans to provide an update on doses for expansion in the latter half of 2024.
The biopharmaceutical company is also developing other TRACTr and TRACIr therapeutics directed at various cancer targets, including a TROP2-targeting TRACTr for multiple cancer types and a dual-targeting TRACIr candidate, JANX009, for solid tumors.
Janux is hosting a virtual investor event today at 4:30 PM Eastern Time to discuss these developments. The live webcast will include a question and answer session, and a replay will be available on the company's website for at least 30 days.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.